M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 4.6 EUR 2.22% Market Closed
Market Cap: 74.2m EUR
Have any thoughts about
Maat Pharma SA?
Write Note
Section:
 

Relative Value

The Relative Value of one MAAT stock under the Base Case scenario is 19.42 EUR. Compared to the current market price of 4.6 EUR, Maat Pharma SA is Undervalued by 76%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MAAT Relative Value
Base Case
19.42 EUR
Undervaluation 76%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

23.1
P/S
P/S
Price to Sales
23.1
vs History
93
vs Industry
26
Median 3Y
50.5
Median 5Y
54
Industry
7.5
Forward
17.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-7.4
Industry
23.6
Forward
-2.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-7.1
Industry
20.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6
Median 5Y
-6.8
Industry
22.9
More Details
7.2
P/B
P/B
Price to Book Value
7.2
vs History
19
vs Industry
30
Median 3Y
5
Median 5Y
5
Industry
2.8
More Details
20.8
EV/S
EV/S
Enterprise Value to Sales
20.8
vs History
93
vs Industry
25
Median 3Y
44.4
Median 5Y
44.6
Industry
7.7
Forward
16.1
More Details
34
EV/GP
EV/GP
Enterprise Value to Gross Profit
34
vs History
91
vs Industry
19
Median 3Y
60.1
Median 5Y
61.1
Industry
9.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-6.4
Industry
4.9
Forward
-1.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-6.2
Industry
4.9
Forward
-1.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-6.2
Industry
5.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-5.8
Industry
4
More Details
7.1
EV/IC
EV/IC
Enterprise Value to IC
7.1
vs History
91
vs Industry
32
Median 3Y
10
Median 5Y
10.3
Industry
5.1
More Details

Multiples Across Competitors

MAAT Competitors Multiples
Maat Pharma SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Maat Pharma SA
PAR:MAAT
74.2m EUR 23.1 -2.6 -2.5 -2.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 917 039.3 -161 202.7 -195 751.4 -193 517.7
US
Abbvie Inc
NYSE:ABBV
339.9B USD 5.9 81.8 15.5 23
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
137.3B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.1B USD 10.9 -122.4 26.1 27.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 077.1 -530 -577.1 -561.7
AU
CSL Ltd
ASX:CSL
116.7B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.2B USD 4.3 13.6 12.2 13.7
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.4 -66.1 -59.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.3B USD 17.6 -153.1 -686.3 -343.9
P/S Multiple
Revenue Growth P/S to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average P/S: 3 083 564.8
23.1
166%
0.1
FR
Pharnext SCA
OTC:PNEXF
33 917 039.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.9
10%
1.1
US
E
Epizyme Inc
F:EPE
2 077.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
S
Seagen Inc
F:SGT
20
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.6
29%
0.6
P/E Multiple
Earnings Growth PEG
FR
M
Maat Pharma SA
PAR:MAAT
Average P/E: 34.6
Negative Multiple: -2.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 202.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.8
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -122.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -153.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBITDA: 15.9
Negative Multiple: -2.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 751.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -686.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBIT: 20.5
Negative Multiple: -2.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 517.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.3
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -343.9 N/A N/A

See Also

Summary
MAAT intrinsic value, competitors valuation, and company profile.
DCF Valuation
MAAT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MAAT stock valuation using valuation multiples.
Wall Street Estimates
MAAT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MAAT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 267,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.